ADARx Pharmaceuticals (NASDAQ:ADRX – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research note issued on Wednesday, Zacks reports. A number of other equities analysts also recently commented on ADRX. JPMorgan Chase & Co. initiated coverage on ADARx Pharmaceuticals in a report on Tuesday. They set […]

ADARx Pharmaceuticals (NASDAQ:ADRX – Get Free Report) was upgraded by stock analysts at UBS Group to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks reports. Other analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of ADARx Pharmaceuticals to a “hold” rating in a report […]

UBS Group started coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research note published on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $109.00 target price on the biotechnology company’s stock. A number of other brokerages have also issued reports on ARWR. Piper Sandler restated an “overweight” rating […]

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by investment analysts at UBS Group to a “strong-buy” rating in a report issued on Wednesday, Zacks reports. ARWR has been the topic of several other research reports. Morgan Stanley lifted their price target on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by investment analysts at UBS Group from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $23.00 price objective on the biopharmaceutical company’s stock. UBS Group’s price target suggests a potential upside of […]